We’re pleased to announce the appointment of Pier Vincenzo Piazza as Aelis Farma’s new CEO.
Piervi’s appointment comes at a key moment in Aelis Farma’s development : the company is currently finalizing its phase 1 studies for AEF0117, its lead compound, and is actively preparing its phase IIa study in the field of cannabis addiction which will be conducted at Columbia University.
Piervi is an MD PhD also trained as a psychiatrist. He has been working full time on translational research since 1988. His particular field of expertise is the pathophysiology of behavior and in particular addiction, which he has been studying for 25 years.
Since 2007 and until his appointment as full time CEO of Aelis Farma, he was the director of the Neurocentre Magendie (INSERM, U862) in Bordeaux. The role of pregnenolone as a signaling specific allosteric inhibitor of the CB1 has been discovered by his research group. He cofounded Aelis Farma and has been acting as the director of its R&D activities until his appointment as CEO.
Previous to Aelis Farma, he cofounded two other biotech companies (Fluofarma and Alienor Farma), the former specialized in High Content Screening and the latter in the development of an anticancer drug. These two previous companies have given him a solid background in entrepreneurship and drug development.
This recent publication by the WHO builds on contributions from a broad range of experts and researchers all over the world. It aims at presenting the current knowledge of the impact of nonmedical cannabis use on health including epidemiology of cannabis disorders, neurobiology and short term effects of cannabis use, mental health/psychosocial outcomes of long term cannabis use. According to WHO data, 16% of countries included in the recent ATLAS survey (Atlas 2015 in press) reported cannabis use as the main reason for people seeking substance abuse treatment. This puts cannabis second only to alcohol as a reason for treatment entry. In this context, the report highlights the urgent need to know more about potential effective pharmacotherapy for cannabis-use disorders.
Aelis Farma attended the JP Morgan Annual Healthcare Conference and 2016 Biotech Showcase in San Francisco. The company presented the latest developments of AEF0117 and AEF0118 to potential partners and investors.
Pier Vincenzo Piazza is awarded the Grand Prix de l’INSERM 2015 in recognition of his career in the field of the physiopathology of psychiatric diseases. The Grand prix de l’INSERM recognizes major advancements in biology for an active researcher of the institution,
Aelis Farma is granted 500.000 euros in subsidy from the Région Aquitaine under a “R&D – technology transfer” program in order to finance the company’s research program to move forward its lead compound, AEF0117, towards IND and first in human clinical trial.
Pier Vincenzo Piazza is awarded the Prix Lamonica in Neurology (Fondation pour la recherche biomédicale – P.C.L) by the French Académie des Sciences for his work on the physiopathology of addictions and of traumatic memories.
Aelis Farma is partnering with the 7th European Cannabinoid Workshop taking place from September 17 to 19 in Sestri Levante, Genoa, Italy.
Find us on : www.cannabinoidconference2015.org
In line with the French government plan for 2013-2017, the MILDECA encourages research around the development of new treatments for populations most exposed to risks related to addictive behaviors. In the field of therapeutical research, the government plan insists on the necessity to favor le development of innovative therapies to fight addiction and psychoactive substances abuses (mesure 94).
This grant rewards the close cooperation between Aelis Farma and the Inserm Neurocenter Magendie.
AEF0118 is periphery restricted and is designed to treat diseases involving the peripheral CB1 receptor such as fibrotic and metabolic diseases. Pre-clinical proof of concept studies using appropriate disease models involving the peripheral CB1 receptor will now be performed to confirm the potential of this compound.
Aelis Farma identifies AEF0117 as its lead compound for cannabis use disorders. Regulatory pre-clinical safety and toxicity studies will take place in 2015, with an aim to file an IND with the FDA early in 2016.